Furthermore, several clinical studies demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RAs) can reduce the risk of dementia in T2DM patients by improving memory and learning and overcoming cognitive impairment [12]. The gene discussed is GLP1R; the disease is dementia.